Zinostatin

03/01/1997 - "Targeting studies using the anti-cancer agent neocarzinostatin (NCS), conjugated to anti-bodies have shown relatively poor specificity. "
12/01/1978 - "Phase I study of neocarzinostatin in children with cancer."
09/01/2008 - "To identify and mathematically model molecular predictors of response to the enediyne chemotherapeutic agent, neocarzinostatin, in nervous system cancer cell lines. "
07/05/1999 - "TES-23, which strongly and selectively recognizes tumor tissue endothelial cells, was chemically conjugated with Neocarzinostatin (NCS), and the anti-tumor effect was examined. "
08/01/1989 - "The authors studied the localization of neocarzinostatin (NCS) in cultured cells and in tumor-bearing rats by means of immunofluorescent staining. "

01/01/1980 - "A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. "
05/01/1982 - "[Efficacy of arterial infusion chemotherapy with neocarzinostatin on inoperable hepatoma]."
11/01/2010 - "Here, we provide genetic evidence that ATM kinase activity is required to trigger 5-FU- and neocarzinostatin-dependent cFLIP(L) and cFLIP(S) down-regulation, which in turn sensitize hepatocellular carcinoma (HCC) cell lines to TRAIL. "
05/01/1982 - "We named this new method "high pressure one hot injection." When we tried to apply this method to patients with inoperable hepatoma, we considered that Neocarzinostatin (NCS) was a very applicable antitumor drug in terms of cell killing kinetics. "
01/01/2000 - "Focal therapeutic efficacy of transcatheter arterial infusion of styrene maleic acid neocarzinostatin for hepatocellular carcinoma."

08/01/1983 - "2. Clinical studies on the administration of neocarzinostatin in advanced and recurrent carcinoma of the pancreas]."
09/01/1992 - "Fate of antibody-neocarzinostatin conjugates bound to human colonic carcinoma cells in vitro."
08/01/1983 - "1. Administration of neocarzinostatin in advanced and recurrent carcinoma of the stomach]."
11/01/1973 - "Survival of clonogenic cells of a murine epithelioma treated with neocarzinostatin."
07/01/1986 - "[Use of arterial infusion of neocarzinostatin with or without combination chemotherapy as a treatment of carcinoma of the prostate]."

11/01/1982 - "In vitro study, the minimum susceptibility of glioblastoma cells to neocarzinostatin was found to be below 0.005 microgram/ml, whereas normal glia cells were not affected at 0.3 microgram/ml. This study indicated that neocarzinostatin was extremely effective in the treatment of malignant brain tumor without affecting normal neural tissue. "
07/01/1982 - "An antitumor protein, neocarzinostatin (NCS) as a prototype drug, has been utilized since it was found effective against glioblastoma cells at extremely low concentration (less than 5 ng/ml) and it is readily inactivated by serum. "
11/01/1982 - "Neocarzinostatin as previously reported, appeared to exhibit an intense cytotoxicity to the glioblastoma cells and some other malignant brain tumor cells, such as pineal germinoma or medulloblastoma, which are notoriously known to disseminate into the cerebrospinal fluid space. "

02/01/1995 - "These observations suggest that the intra-tumoural injection of neocarzinostatin conjugated to MAb A7 offers promise in treating pancreatic carcinoma."
05/01/1996 - "Effects of neocarzinostatin-chimeric Fab conjugates on the growth of human pancreatic carcinoma xenografts."
02/01/1995 - "Neocarzinostatin conjugated to MAb A7 showed greater activity against human pancreatic cancer than neocarzinostatin alone after both intravenous and intra-tumoural administration. "
08/01/1993 - "Neocarzinostatin conjugated to MAb A7 showed a greater antitumor activity against human pancreatic cancer than neocarzinostatin alone after intratumoral administration. "
12/20/1975 - "[The treatment of pancreatic carcinoma with neocarzinostatin]."